The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Apr / Making the Media of the Future – Today
Manufacture Bioprocessing Biopharma Sponsored

Making the Media of the Future – Today

Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.

04/21/2017 1 min read

Share

In previous articles in this series, we heard about intensified perfusion systems from Delia Lyons (1), and about high-density cryopreservation from Jochen Sieck (2). Now, Lyons is joined by Jeremiah Riesberg (Senior Scientist, Perfusion Medium Development, Millipore Sigma, USA) to discuss a novel culture medium. The product, currently in beta testing with chosen clients, has been designed for the most challenging of applications – intensified perfusion at steady state – but is also applicable to a range of other processes.

Figure 1: Final medium (M3) could maintain a target cell density with a 40pL/cell/d with a 50 percent increase in specific productivity compared to prototype M1.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. D Lyons, “An Intense Focus on Perfusion”, The Medicine Maker, 27 (2017). Available at: http://bit.ly/2mF5Dqp. JB Sieck, “Freezing Down Time in Bioprocessing”, The Medicine Maker, 28 (2017). Available at: http://bit.ly/2nK7wzD.

Recommended

Related Content

Musings from The Power List: Andres Sirulnik
Development & Clinical Biopharma Interviews
Musings from The Power List: Andres Sirulnik

October 5, 2026

4 min read

Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines

Musings from The Power List: Renee Aguiar-Lucander
Biopharma Development & Clinical Interviews
Musings from The Power List: Renee Aguiar-Lucander

September 28, 2026

2 min read

Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner

The Manufacturing Questions Facing Chinese Biotech
Biopharma Business & Trends Technology & Manufacturing
The Manufacturing Questions Facing Chinese Biotech

September 9, 2026

5 min read

Lonza’s Wayne Wen discusses the growing maturity of China’s drug development and manufacturing ecosystem – and what companies need to compete internationally

China’s Biopharma Homecoming
Biopharma Biopharma Regulation & Standards
China’s Biopharma Homecoming

September 1, 2026

7 min read

Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: